The impact of ABCB1 , CYP3A4 and CYP3A5 gene polymorphisms on apixaban trough concentration and bleeding risk in patients with atrial fibrillation.

Alena I SkripkaPavel M KrupeninOlga N KozhanovaAnna A KudryavtsevaLudmila V FedinaKristina A AkmalovaPavel O BochkovAnastasiya A SokolovaDmitriy A NapalkovDmitriy A Sychev

Published in: Drug metabolism and personalized therapy (2024)

(rs776746) A>G and bleeding events on apixaban treatment. Complementing the existing criteria with pharmacogenetic and pharmacokinetics information for the patients with AF will enable further individualization of apixaban.

Keyphrases

atrial fibrillation
venous thromboembolism
healthcare
combination therapy
social media
replacement therapy